Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare

Nature Biotechnology volume 21, pages 747–753 (2003)Cite this article

As the first products based on pharmacogenomics emerge, economic and regulatory considerations will affect—and be affected by—drug approval, licensing and delivery long before medicines are prescribed by a physician.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The complexity of pharmacogenomics.

©Rebecca Henretta

Figure 2: Individualized response to drugs—current and future.

©Rebecca Henretta

References

  1. Lindpaintner, K. Pharmacogenetics and the future of medical practice: conceptual considerations. Pharmacogenomics J. 1, 23–26 (2001).

    Article  CAS  Google Scholar 

  2. Tollman, P., Guy, P., Altshuler, J., Flanagan, A. & Steiner, M. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry (The Boston Consulting Group, Boston, MA, 2001).

    Google Scholar 

  3. Snedden, R. Pharmacogenetics Workshop: Background Paper (The Wellcome Trust, London, 1999).

    Google Scholar 

  4. Hodgson, J. & Marshall, A. Pharmacogenomics: will the regulators approve? Nat. Biotechnol. 16, 243–246 (1998).

    Article  CAS  Google Scholar 

  5. Robertson, J.A., Brody, B., Buchanan, A., Kahn, J. & McPherson, E. Pharmacogenetic challenges for the health care system. Health Aff. 21, 155–167 (2002).

    Article  Google Scholar 

  6. Ledley, F.D. Can pharmacogenetics make a difference in drug development? Nat. Biotechnol. 17, 731 (1999).

    Article  CAS  Google Scholar 

  7. Lindpaintner, K. The importance of being modest: reflections on the pharmacogenetics of Abacavir. Pharmacogenomics 3, 835–838 (2002).

    Article  Google Scholar 

  8. Thomas, S.M. Pharmacogenetics: the ethical context. Pharmacogenomics J. 1, 239–242 (2001).

    Article  CAS  Google Scholar 

  9. Lindpaintner, K. Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases. Br. Med. Bull. 55, 471–491 (1999).

    Article  CAS  Google Scholar 

  10. Roses, A.D. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).

    Article  CAS  Google Scholar 

  11. Norton, R.M. Clinical pharmacogenetics: applications in pharmaceutical R&D. Drug Discov. Today 6, 180–186 (2001).

    Article  Google Scholar 

  12. Owens, J., Ramster, B. & Lawrence, R.N. Impact of SNP genotyping could save millions by 2010. Drug Discov. Today 6, 450 (2001).

    Google Scholar 

  13. Birmingham, K. Experts predict bleak post-genomic era for drug R&D. Nat. Med. 7, 262 (2001).

    Article  CAS  Google Scholar 

  14. Hawkes, N. Medicines priced high to recoup research and marketing cost. The Times, August 13 (2002), p. 4.

  15. Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463–469 (2002).

    Article  CAS  Google Scholar 

  16. Ward, S.J. Impact of genomics in drug discovery. BioTechniques (Euro Edition), 64–69 (2001).

  17. Rothstein, M.A. & Epps, P.G. Ethical and legal implications of pharmacogenomics. Nat. Rev. Genet. 2, 228–231 (2001).

    Article  CAS  Google Scholar 

  18. Issa, A.M. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1, 300–308 (2002).

    Article  CAS  Google Scholar 

  19. Spallone, P. & Wilkie, T. Social, Ethical, and Public Policy Implications of Advances in the Biomedical Sciences: The Wellcome Trust's Initiative on Pharmacogenetics (The Wellcome Trust, London, 1999).

  20. Wolf, C.R. & Smith, G. Pharmacogenetics. Br. Med. Bull. 55, 366–386 (1999).

    Article  CAS  Google Scholar 

  21. Broder, S. & Venter, J.C. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Annu. Rev. Pharmacol. Toxicol. 40, 97–132 (2000).

    Article  CAS  Google Scholar 

  22. Borst-Eilers, E. Availability of pharmaceutical drugs. Lancet 356, 6 (2000).

    Article  Google Scholar 

  23. Furberg, C.D., Herrington, D.M. & Psaty, B.M. Are drugs within a class interchangeable? Lancet 354, 1202–1204 (1999).

    Article  CAS  Google Scholar 

  24. Shah, R.R. Regulatory aspects of integration of pharmacogenetics into drug development. Int. J. Pharmceut. Med. 15, 67–69 (2001).

    Google Scholar 

  25. US Food and Drug Administration. Improving innovation in medical technology: beyond 2002 (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2003/beyond2002/report.html (31 January 2003).

  26. US Food and Drug Administration. FDA establishes office of combination products (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2002/NEW00862.html (31 December 2002).

  27. Fogarty, M. Up for adoption: pharmacogenetics and the orphan drug law. HMS Beagle 44, http://news.bmn.com/hmsbeagle/, 11 December 1998.

  28. Milne, C.-P. Orphan products—pain relief for clinical development headaches. Nat. Biotechnol. 20, 780–784 (2002).

    Article  CAS  Google Scholar 

  29. Haffner, M.E., Whitley, J. & Moses, M. Two decades of orphan product development. Nat. Rev. Drug Discov. 1, 821–825 (2002).

    Article  CAS  Google Scholar 

  30. Lesko, L. & Woodcock, J. Pharmacogenetic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20–24 (2002).

    Article  CAS  Google Scholar 

  31. Branca, M. FDA fosters pharmacogenomics. Bio-ITWorld, 1, 45 (2002).

    Google Scholar 

  32. US Food and Drug Administration. Gleevec approved for first line treatment of chronic myeloid leukemia (CML) (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2002/NEW00860.html (20 December 2002).

  33. McCarthy, M. FDA allows controversial bowel drug back on to market. Lancet 359, 2095 (2002).

    Article  Google Scholar 

  34. US Food and Drug Administration. FDA approves restricted marketing of Lotronex (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2002/NEW00814.html (7 June 2002).

  35. Lasser, K.E. et al. Timing of new black box warnings and withdrawals of prescription medications. JAMA 287, 2215–2220 (2002).

    Article  Google Scholar 

  36. US Food and Drug Administration. FDA and Lincoln Technologies, Inc. to collaborate on developing tools for safety data mining. (USFDA, Rockville, Maryland) http://www.fda.gov/bbs/topics/NEWS/2003/NEW00899.html (1 May 2003).

  37. Loyd, L. An end to vaccine for Lyme disease. The Philadelphia Inquirer, 27 February 2002, p. C1.

  38. Editorial. Pharmacogenomics at work. Nat. Biotechnol. 16, 885 (1998).

  39. Eggertson, L. Ontario defies US firm's genetic patent, continues cancer screening. Can. Med. Assoc. J. 166, 494 (2002).

    Google Scholar 

  40. Claxton, K., Schulpher, M. & Drummond, M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 360, 711–715 (2002).

    Article  Google Scholar 

  41. Bloor, K., Maynard, A. & Freemantle, N. Lessons from international experiences in controlling pharmaceutical expenditure III: regulating industry. Br. Med. J. 313, 33–35 (1996).

    Article  CAS  Google Scholar 

  42. National Institute for Clinical Excellence. Technology Appraisal Guidance No.34—Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. (National Institute for Clinical Excellence, London, 2002).

  43. Rennie, D. & Luft, H.S. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 283, 2158–2160 (2000).

    Article  CAS  Google Scholar 

  44. BBC News Online. Relief over breast drug decision. British Broadcasting Corporation, http://news.bbc.co.uk/1/hi/health/1874368.stm, 15 March 2002.

  45. BBC News Online. Two sides of the Herceptin lottery. British Broadcasting Corporation, http://news.bbc.co.uk/1/hi/health/1873433.stm, 15 March 2002.

  46. Watanabe, M.E. Skeptical scientists skewer VaxGen statistics. Nat. Med. 9, 376 (2003).

    Article  CAS  Google Scholar 

  47. Rothstein, M.A. & Epps, P.G. Pharmacogenomics and the (ir)relevance of race. Pharmacogenomics J. 1, 104–108 (2001).

    Article  CAS  Google Scholar 

  48. Editorial. Genes, drugs and race. Nat. Genet. 29, 239–240 (2001).

  49. Schwartz, R.S. Racial profiling in medical research. N. Engl. J. Med. 344, 1392–1393 (2001).

    Article  CAS  Google Scholar 

  50. Wood, A.J.J. Racial differences in the response to drugs—pointers to genetic differences. N. Engl. J. Med. 344, 1393–1396 (2001).

    Article  Google Scholar 

  51. Lipton, P. Pharmacogenetics: the ethical issues. Pharmacogenomics J. 3, 14–16 (2003).

    Article  CAS  Google Scholar 

  52. Veenstra, D.L., Higashi, M.K. & Phillips, K.A. Assessing the cost-effectiveness of pharmacogenetics. AAPS PharmSci 2, E29 (2000).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I am grateful to the secretariat of the Nuffield Council on Bioethics, in particular Sandy Thomas and Harald Schmidt for their hospitality during my internship; and to them, Elias Mossialos and Timothy Caulfield for their valuable comments on the early text of this paper. My conclusions do not necessarily reflect the views of the Council or its Working Party on Pharmacogenetics. Research for this paper was funded through a Commonwealth Scholarship held in the Department of Social Policy, London School of Economics and Political Science.

Author information

Authors and Affiliations

  1. Department of Social Policy, London School of Economics and Political Science,

    Jai Shah

  2. Canadian Institutes of Health Research, 410 Laurier Avenue West (11th Floor), Ottawa, K1A 0W9, Ontario, Canada

    Jai Shah

Authors
  1. Jai Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nat Biotechnol 21, 747–753 (2003). https://doi.org/10.1038/nbt0703-747

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0703-747

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing